Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
| Condition(s) | Ovarian Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study. |
| Who can participate | Inclusion Criteria: * This study will enroll women with platinum resistant high grade serous ovarian cancer. * This study is open to minorities as appropriate but is not designed to measure differences in intervention effects. * All patients must be registered for screening prior to study enrollment, however, if biomarker testing results are not required prior to enrollment to a substudy, then enrollment can proceed immediately. CCTG will advise sites when biomarker testing results are required prior to substudy enrollment. Additional Criteria To Be Met Prior To Sub-study Enrollment All patients must fulfill all of the following criteria to be eligible for enrollment to the study. Additional eligibility criteria and relevant timings that are specific to a substudy are listed in each substu |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | Canadian Cancer Trials Group |
| Locations | Chicago, Illinois, United States; Kelowna, British Columbia, Canada; Vancouver, British Columbia, Canada; Toronto, Ontario, Canada; Toronto, Ontario, Canada; Montreal, Quebec, Canada (+1 more sites) |
| Start date | 2022-05-03 |
| NCT ID | NCT04918186 |
| Official listing | https://clinicaltrials.gov/study/NCT04918186 |